WO2011149438A1 - Combination of antihypertensive agents - Google Patents
Combination of antihypertensive agents Download PDFInfo
- Publication number
- WO2011149438A1 WO2011149438A1 PCT/TR2011/000153 TR2011000153W WO2011149438A1 WO 2011149438 A1 WO2011149438 A1 WO 2011149438A1 TR 2011000153 W TR2011000153 W TR 2011000153W WO 2011149438 A1 WO2011149438 A1 WO 2011149438A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- composition according
- cellulose
- sodium
- calcium
- Prior art date
Links
- 229940030600 antihypertensive agent Drugs 0.000 title description 2
- 239000002220 antihypertensive agent Substances 0.000 title description 2
- 239000013543 active substance Substances 0.000 claims abstract description 41
- 206010020772 Hypertension Diseases 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 51
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 41
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 31
- 229960004569 indapamide Drugs 0.000 claims description 31
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 27
- 229960000528 amlodipine Drugs 0.000 claims description 27
- -1 methyl hydroxypropyl Chemical group 0.000 claims description 27
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 24
- 229960005187 telmisartan Drugs 0.000 claims description 24
- 239000003826 tablet Substances 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 235000010980 cellulose Nutrition 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 150000005215 alkyl ethers Chemical class 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 229960004106 citric acid Drugs 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 235000011087 fumaric acid Nutrition 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
- 239000000347 magnesium hydroxide Substances 0.000 claims description 4
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 4
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 4
- 239000000391 magnesium silicate Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 230000003711 photoprotective effect Effects 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 4
- 239000004554 water soluble tablet Substances 0.000 claims description 4
- 239000001993 wax Substances 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229960005069 calcium Drugs 0.000 claims description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 235000011132 calcium sulphate Nutrition 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 235000001055 magnesium Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 2
- 206010001580 Albuminuria Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 240000000560 Citrus x paradisi Species 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 244000018633 Prunus armeniaca Species 0.000 claims description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 2
- 235000005805 Prunus cerasus Nutrition 0.000 claims description 2
- 244000207449 Prunus puddum Species 0.000 claims description 2
- 235000009226 Prunus puddum Nutrition 0.000 claims description 2
- 235000014443 Pyrus communis Nutrition 0.000 claims description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010039808 Secondary aldosteronism Diseases 0.000 claims description 2
- 239000004115 Sodium Silicate Substances 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
- 239000000378 calcium silicate Substances 0.000 claims description 2
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000001175 calcium sulphate Substances 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 239000007958 cherry flavor Substances 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 239000007950 delayed release tablet Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- 229960000878 docusate sodium Drugs 0.000 claims description 2
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims description 2
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 201000009939 hypertensive encephalopathy Diseases 0.000 claims description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 2
- 239000002563 ionic surfactant Substances 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 2
- 239000011654 magnesium acetate Substances 0.000 claims description 2
- 235000011285 magnesium acetate Nutrition 0.000 claims description 2
- 229940069446 magnesium acetate Drugs 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 229960001708 magnesium carbonate Drugs 0.000 claims description 2
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 2
- 229960000816 magnesium hydroxide Drugs 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940099690 malic acid Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
- 150000004692 metal hydroxides Chemical class 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 239000007912 modified release tablet Substances 0.000 claims description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 239000004223 monosodium glutamate Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 2
- 239000007968 orange flavor Substances 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 229920001592 potato starch Polymers 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- 235000010388 propyl gallate Nutrition 0.000 claims description 2
- 229940075579 propyl gallate Drugs 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- 150000004760 silicates Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229910001388 sodium aluminate Inorganic materials 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 235000010265 sodium sulphite Nutrition 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims description 2
- 239000007944 soluble tablet Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 claims description 2
- 239000001959 sucrose esters of fatty acids Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000001732 thrombotic effect Effects 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000004549 water soluble granule Substances 0.000 claims description 2
- 239000004552 water soluble powder Substances 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 6
- 230000003276 anti-hypertensive effect Effects 0.000 abstract description 4
- 229960001375 lactose Drugs 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FWFGVMYFCODZRD-UHFFFAOYSA-N oxidanium;hydrogen sulfate Chemical compound O.OS(O)(=O)=O FWFGVMYFCODZRD-UHFFFAOYSA-N 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940043097 telmisartan and amlodipine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a combination of antihypertensive active agents; methods for preparation of said combination; and use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
- the present invention relates to use of the active agents a) mdapamide which is a diuretic, b) amlodipine which is a calcium channel blocker and c) telmisartan which is an angiotensin receptor antagonist in combination.
- Indapamide chemical name of which is 4-chloro-N-(2-methylindolyn-l-yl)-3-sulfamoyl- benzamide, was first disclosed in the patent numbered US 3565911. There exist various processes for preparation of the molecule indapamide and pharmaceutical compositions comprising the active agent indapamide in the prior art. It is known that indapamide is indicated in the treatment of hypertension and edema.
- Amlodipine chemical name of which is 3-ethyl 5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4- (o-cUorophenyl)-l,4-dmydropyridme-6-memyl-3,5-pyridinedicarboxylate, was disclosed in the patent numbered EP 0089167 in detail.
- telmisartan The molecule telmisartan, chemical name of which is 4'-[(l,4-dimethyl-2'-propyl[2,6-bi-lH- benzimidazo l]- -yl)meyl]-[l, -biphenyl)-2-carboxylic acid, was disclosed in the patent numbered EP 0502314.
- telmisartan chemical name of which is 4'-[(l,4-dimethyl-2'-propyl[2,6-bi-lH- benzimidazo l]- -yl)meyl]-[l, -biphenyl)-2-carboxylic acid
- the present invention relates to combined use of the active agents indapamide (formula I) which is a diuretic; amlodipine (formula II) which is a calcium channel blocker; and telmisartan (formula III) which is an angiotensin receptor antagonist.
- telmisarta The present invention comprises use of the active agents indapamide, amlodipine and telmisartan in combination. In addition, it also comprises optional use of pharmaceutically acceptable excipients in said composition.
- the active agents of the combination of the present invention can be in free form or in the forms of pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms and amorphous forms of the respective active agents.
- the active agent amlodipine in the combination of the present invention is preferably in the form of pharmaceutically acceptable salt thereof.
- besylate salt of amlodipine which can be in the form of besylate, mesylate or maleate salt, is used.
- the present invention relates to use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
- hypertension-related diseases and various cardiovascular diseases refers to diseases such as acute and/or chronic heart failure, congestive heart failure, left heart failure, hypertrophic cardiomyopathy, arrhythmia, cardiomegalia, atrial fibrillation, embolism, ischemic heart disease, coronary artery disease, myocardial infarction, atherosclerosis, angina, renal failure, angina pectoris, diabetes, secondary aldosteronism, pulmonary hypertension, diabetic nephropathy, scleroderma, glomerulosclerosis, albuminuria, diabetic retinopathy, migraine, peripheral vascular diseases, Raynaud's phenomenon, cognitive disorders, hypertensive encephalopathy, thrombotic glaucoma and stroke.
- Pharmaceutical compositions comprising the combination of the present invention can be used simultaneously, sequentially or separately.
- the active agents of the composition of the present invention can be formulated separately so as to be used in a kit form.
- the present invention relates to administration of said combination in warm blooded animals in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
- the present invention relating to use of a pharmaceutical composition to be used in the manufacture of an effective drug for the treatment of hypertension, hypertension related diseases and various cardiovascular diseases is characterized by comprising the active agents indapamide, amlodipine and telmisartan.
- the composition comprising the active agents telmisartan, amlodipine and indapamide can be prepared to be used by the oral route.
- compositions of the present invention comprises oral dosage forms and their pharmaceutical formulations which optionally comprise pharmaceutically acceptable excipients in addition to the active agents.
- Oral dosage forms can be in solid dosage forms such as tablet; capsule; enteric coated or modified release tablets; prolonged release tablet; delayed release tablet; fast soluble tablet; effervescent tablet; effervescent granule; fast soluble powder mixture or dry powder mixture for syrup preparation; dragee; orally disintegrating tablet; water soluble tablet; water soluble powder, tablet or granule; film tablet; or liquid dosage forms such as suspension.
- the amount of active agent in the formulation of the present invention can vary in the range of 0.5% to 95%, preferably in the range of 1% to 90% in proportion to total amount of substances in the pharmaceutical formulation.
- Dose of the active agent in the pharmaceutical formulation can vary according to the route of administration; patient's age and state of health.
- one dose of the pharmaceutical composition comprising the present invention can comprise 10-300 mg telmisartan; 2,5-25 mg amlodipine; 0,1-10 mg indapamide.
- the composition of the present invention is composed of the active agents telmisartan, amlodipine and indapamide. Desired therapeutic action time is obtained by intake of telmisartan and amlodipine once a day. However, this is not possible for indapamide.
- the inventors considered to formulate the combination in compressed bilayer tablet form in order to equalize action times of the active agents. Antihypertensive action times of the active agents of the composition can be equalized by comprising indapamide, which has shorter hypertensive action time compared with the other active agents in the composition, both in the fast release layer and the constant release layer. More effective compositions have been obtained by formulating the combination of the present invention in compressed bilayer tablet form.
- the constant release layer comprising indapamide is the innermost layer of the tablet.
- Fast release layer comprising telmisartan, amlodipine and indapamide, on the other hand, is placed around the constant release layer.
- tablet forms are obtained such that the coating is the outermost layer of the tablet.
- polymers can be used in order to provide constant release of indapamide.
- Polymers ensuring constant release can be selected from, but not limited to, a group comprising cellulose derivatives, particularly hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, methyl hydroxypropyl cellulose, carboxymethyl cellulose, povidone; acrylic acid copolymers or combinations thereof.
- compositions comprising the combinations of antihypertensive active agents are produced according to conventional techniques optionally with addition of pharmaceutically acceptable excipients.
- excipients can also be used in addition to the active agents used in each oral formulation.
- excipients can be components such as at least one binder, lubricant, disintegrant, demulsifying agent, stabilizing agent, flavoring agent, diluent, surfactant and glidant.
- binders can be selected from, but not limited to, the group comprising starches (such as potato starch, corn starch, wheat starch); sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums (such as acacia); gelatin; cellulose derivatives (such as macrocrystalline cellulose, HPC, HEC, HPMC, carboxymethyl cellulose, methyl cellulose, ethyl cellulose); povidone, polyvinylpyrrolidone, polyethylene glycol; waxes; calcium carbonate; calcium phosphate; alcohols (such as sorbitol, xylitol, mannitol) and water.
- starches such as potato starch, corn starch, wheat starch
- sugars such as sucrose, glucose, dextrose, lactose, maltodextrin
- natural and synthetic gums such as acacia
- gelatin such as macrocrystalline cellulose, HPC, HEC, HPMC, carboxy
- Pharmaceutically acceptable lubricant can be selected from, but not limited to, the group comprising stearic acid, stearic acid salts (calcium state, magnesium stearate, etc.), talc, colloidal silica, wax, boric acid, adipic acid, sulfates (sodium sulfate), glycol, fumaric acid, sodium benzoate, DL-leucine, lauryl sulfate (sodium lauryl sulfate, magnesium lauryl sulfate, etc.), silicates, starch derivatives.
- Pharmaceutically acceptable disintegrants can be selected from, but not limited to, the group comprising cellulose derivatives (low-substituted hydoxypropyl cellulose, carboxymethylcellulose, calciumcarboxymethylcellulose, cross-linked sodium carboxymethyl cellulose) and chemically modified starch/cellulose derivatives (carboxymethyl starch, sodiumcarboxymethyl starch, etc.).
- compositionsifying agents can be selected from, but not limited to, the group comprising colloidal clay (bentonite, etc.), metal hydroxides (magnesium hydroxide, aluminum hydroxide, etc.), anionic surfactant (sodium lauryl sulfate, calcium stearate, etc.), cationic surfactant or ionic surfactant (polyoxyethylene alkyl ether, fatty acid ester of polyoxyethylene sorbitan or sucrose esters of fatty acids).
- colloidal clay bentonite, etc.
- metal hydroxides magnesium hydroxide, aluminum hydroxide, etc.
- anionic surfactant sodium lauryl sulfate, calcium stearate, etc.
- cationic surfactant or ionic surfactant polyoxyethylene alkyl ether, fatty acid ester of polyoxyethylene sorbitan or sucrose esters of fatty acids.
- Stabilizing agent and/or agents can be selected from agents such as antioxidants, chelating agents, alkalinizing agents and photoprotective agents.
- Antioxidants can be selected from, but not limited to, the group comprising substances such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium sulfite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylsistein, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
- BHA butylated hydroxyanisole
- BHT butylated hydroxytoluene
- gallates such as propyl gallate
- tocopherol citric acid, malic acid, ascorbic acid, acetylsistein, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
- Chelating agents can be selected from, but not limited to, the group comprising disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
- Alkalinizing agents can be selected from, but not limited to, alkali metal salts such as sodium carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines, ⁇ , ⁇ '- dibenzylemylenediamine, diemanolamine, ethylenediamine, meglumine, monosodium glutamate, polacryline sodium, sodium alginate.
- Photoprotective agents can be selected from, but not limited to, a group comprising metal oxides such as titanium oxide, iron oxide or zinc oxide.
- Pharmaceutically acceptable flavoring agents can be selected from, but not limited to, the group comprising sour cherry flavor, blackberry flavor, grapefruit flavor, grape flavor, pear flavor, orange flavor, apricot flavor or combinations thereof.
- Pharmaceutically acceptable diluents can be selected from, but not limited to, the group comprising lactose, dry lactose, lactose monohydrate, directly compressed lactose (lactose D.C.), starch, hydrolyzed starch, mannitol, sorbitol, xylitol, dextrose, dextrose monohydrate, dibasic calcium phosphate dihydrate, monobasic calcium, sulfate monohydrate, calcium sulfate dihydrate, amylose, calcium carbonate, glycine, bentonite.
- compositions can be selected from, but not limited to, the group comprising sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, sugar esters of fatty acids and glycerides of fatty acids.
- glidants can be selected from, but not limited to, the group comprising talc, silicone dioxide, magnesium trisilicate, cellulose powder, starch, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfates.
- solubility modulators such as solubility modulators, sweeteners, coloring agents and coating agents can also be used in the formulation.
- telmisartan, amlodipine and indapamide are turn into a pharmaceutical composition by conventional methods in the prior art.
- the homogenous mixture obtained afterwards is dried and shaped as required.
- Preparation of the bilayer tablet composed of a fast release and a constant release layer comprises the following steps:
- the constant release layer is prepared.
- indapamide constitutes 5% of total amount of substances and pharmaceutically acceptable excipients with polymers providing constant release characteristic in addition.
- Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and sieved. They are mixed so as to provide homogeneity.
- telmisartan a layer which comprises telmisartan, amlodipine and indapamide surrounding the constant release layer.
- This layer is prepared according to conventional tablet production methods with the addition of all the active agents and pharmaceutically acceptable excipients.
- the pharmaceutical composition comprises 5% indapamide; 10% amlodipine and 30% telmisartan of total substance amount. Afterwards, the homogenous mixture obtained is dried and shaped as required.
- Both mixtures prepared are pressed as bilayer tablet by imposing an appropriate compressive force. Firstly, the constant release layer is pressed, then the fast release layer is pressed around it.
- the tablet is coated with pharmaceutically acceptable coating materials.
- indapamide there is 2,5% indapamide in proportion to total substance amount of the pharmaceutical formulation in the constant release layer which is the innermost layer of the tablet.
- polymers such as hydroxypropyl methyl cellulose, microcrystalline cellulose are added.
- Other excipients are also added into the pharmaceutical composition.
- Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and then sieved. They are mixed so as to provide homogeneity.
- the fast release layer surrounding the constant release layer comprises 5% indapamide, 10% amlodipine and 35% telmisartan in proportion to total substance amount of the pharmaceutical formulation.
- Said active agents are mixed with pharmaceutically acceptable excipients.
- Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and then sieved. They are mixed so as to provide homogeneity.
- composition is pressed into tablet form such that the constant release layer is the inner layer while the fast release layer is the outer layer.
- the tablet is coated with pharmaceutically acceptable coating materials.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a combination of a antihypertensive active agents; methods for preparation of said combination; and use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
Description
COMBINATION OF ANTIHYPERTENSIVE AGENTS
The present invention relates to a combination of antihypertensive active agents; methods for preparation of said combination; and use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases. The present invention relates to use of the active agents a) mdapamide which is a diuretic, b) amlodipine which is a calcium channel blocker and c) telmisartan which is an angiotensin receptor antagonist in combination.
Indapamide, chemical name of which is 4-chloro-N-(2-methylindolyn-l-yl)-3-sulfamoyl- benzamide, was first disclosed in the patent numbered US 3565911. There exist various processes for preparation of the molecule indapamide and pharmaceutical compositions comprising the active agent indapamide in the prior art. It is known that indapamide is indicated in the treatment of hypertension and edema.
Amlodipine, chemical name of which is 3-ethyl 5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4- (o-cUorophenyl)-l,4-dmydropyridme-6-memyl-3,5-pyridinedicarboxylate, was disclosed in the patent numbered EP 0089167 in detail. There exist synthesis methods related with amlodipine and pharmaceutical compositions comprising amlodipine; use of the active agent amlodipine in diseases such as angina, variant angina and hypertension in the prior art.
The molecule telmisartan, chemical name of which is 4'-[(l,4-dimethyl-2'-propyl[2,6-bi-lH- benzimidazo l]- -yl)meyl]-[l, -biphenyl)-2-carboxylic acid, was disclosed in the patent numbered EP 0502314. In addition, there exist studies conducted with the molecule telmisartan; synthesis of the molecule telmisartan and pharmaceutical compositions comprising the molecule telmisartan in the prior art. Telmisartan is an active agent indicated in the treatment of hypertension.
Hypertension treatments in which angiotensin receptor antagonists, calcium channel blockers or diuretics are used alone are known in the prior art. However, said monotherapies remain insufficient for most patients.
When the prior art is taken into consideration, there is need for novel pharmaceutical compositions which are used in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases and yield more effective and certain results compared with existing therapies.
The inventors have surprisingly found that combination of the active agents indapamide, amlodipine and telmisartan induces synergistic effect in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases. The combination of the present invention provides greater therapeutic benefit in comparison with the treatment in which indapamide, amlodipine or telmisartan are used alone or two of these active agents are combined.
The present invention relates to combined use of the active agents indapamide (formula I) which is a diuretic; amlodipine (formula II) which is a calcium channel blocker; and telmisartan (formula III) which is an angiotensin receptor antagonist.
In another aspect, the active agents of the combination of the present invention can be in free form or in the forms of pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms and amorphous forms of the respective active agents.
In another aspect, the active agent amlodipine in the combination of the present invention is preferably in the form of pharmaceutically acceptable salt thereof. Preferably, besylate salt of amlodipine, which can be in the form of besylate, mesylate or maleate salt, is used. In another aspect, the present invention relates to use of said combination in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
According to the invention, "hypertension-related diseases and various cardiovascular diseases" refers to diseases such as acute and/or chronic heart failure, congestive heart failure, left heart failure, hypertrophic cardiomyopathy, arrhythmia, cardiomegalia, atrial fibrillation, embolism, ischemic heart disease, coronary artery disease, myocardial infarction, atherosclerosis, angina, renal failure, angina pectoris, diabetes, secondary aldosteronism, pulmonary hypertension, diabetic nephropathy, scleroderma, glomerulosclerosis, albuminuria, diabetic retinopathy, migraine, peripheral vascular diseases, Raynaud's phenomenon, cognitive disorders, hypertensive encephalopathy, thrombotic glaucoma and stroke. Pharmaceutical compositions comprising the combination of the present invention can be used simultaneously, sequentially or separately.
In another aspect, the active agents of the composition of the present invention can be formulated separately so as to be used in a kit form.
In the present invention, it has been seen that an effective use is provided by formulating the pharmaceutical composition comprising the combination of the present invention in the same dosage form.
The present invention relates to administration of said combination in warm blooded animals in the treatment of hypertension, hypertension-related diseases and various cardiovascular diseases.
In another aspect, the present invention relating to use of a pharmaceutical composition to be used in the manufacture of an effective drug for the treatment of hypertension, hypertension related diseases and various cardiovascular diseases is characterized by comprising the active agents indapamide, amlodipine and telmisartan. According to present invention, the composition comprising the active agents telmisartan, amlodipine and indapamide can be prepared to be used by the oral route.
Pharmaceutical compositions of the present invention comprises oral dosage forms and their pharmaceutical formulations which optionally comprise pharmaceutically acceptable excipients in addition to the active agents. Oral dosage forms can be in solid dosage forms such as tablet; capsule; enteric coated or modified release tablets; prolonged release tablet; delayed release tablet; fast soluble tablet; effervescent tablet; effervescent granule; fast soluble powder mixture or dry powder mixture for syrup preparation; dragee; orally disintegrating tablet; water soluble tablet; water soluble powder, tablet or granule; film tablet; or liquid dosage forms such as suspension. According to the invention, the amount of active agent in the formulation of the present invention can vary in the range of 0.5% to 95%, preferably in the range of 1% to 90% in proportion to total amount of substances in the pharmaceutical formulation. Dose of the active agent in the pharmaceutical formulation can vary according to the route of administration; patient's age and state of health. In another aspect, one dose of the pharmaceutical composition comprising the present invention can comprise 10-300 mg telmisartan; 2,5-25 mg amlodipine; 0,1-10 mg indapamide.
The composition of the present invention is composed of the active agents telmisartan, amlodipine and indapamide. Desired therapeutic action time is obtained by intake of telmisartan and amlodipine once a day. However, this is not possible for indapamide. At this point, the inventors considered to formulate the combination in compressed bilayer tablet form in order to equalize action times of the active agents. Antihypertensive action times of the active agents of the composition can be equalized by comprising indapamide, which has shorter hypertensive action time compared with the other active agents in the composition, both in the fast release layer and the constant release layer. More effective compositions have
been obtained by formulating the combination of the present invention in compressed bilayer tablet form.
According to the present invention, the constant release layer comprising indapamide is the innermost layer of the tablet. Fast release layer comprising telmisartan, amlodipine and indapamide, on the other hand, is placed around the constant release layer. By imposing sufficient compressive force, tablet forms are obtained such that the coating is the outermost layer of the tablet.
In another aspect, various polymers can be used in order to provide constant release of indapamide. Polymers ensuring constant release can be selected from, but not limited to, a group comprising cellulose derivatives, particularly hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, methyl hydroxypropyl cellulose, carboxymethyl cellulose, povidone; acrylic acid copolymers or combinations thereof.
Pharmaceutical compositions comprising the combinations of antihypertensive active agents are produced according to conventional techniques optionally with addition of pharmaceutically acceptable excipients.
According to the present invention, pharmaceutically acceptable excipients can also be used in addition to the active agents used in each oral formulation. These excipients can be components such as at least one binder, lubricant, disintegrant, demulsifying agent, stabilizing agent, flavoring agent, diluent, surfactant and glidant.
Pharmaceutically acceptable binders can be selected from, but not limited to, the group comprising starches (such as potato starch, corn starch, wheat starch); sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums (such as acacia); gelatin; cellulose derivatives (such as macrocrystalline cellulose, HPC, HEC, HPMC, carboxymethyl cellulose, methyl cellulose, ethyl cellulose); povidone, polyvinylpyrrolidone, polyethylene glycol; waxes; calcium carbonate; calcium phosphate; alcohols (such as sorbitol, xylitol, mannitol) and water.
Pharmaceutically acceptable lubricant can be selected from, but not limited to, the group comprising stearic acid, stearic acid salts (calcium state, magnesium stearate, etc.), talc, colloidal silica, wax, boric acid, adipic acid, sulfates (sodium sulfate), glycol, fumaric acid,
sodium benzoate, DL-leucine, lauryl sulfate (sodium lauryl sulfate, magnesium lauryl sulfate, etc.), silicates, starch derivatives.
Pharmaceutically acceptable disintegrants can be selected from, but not limited to, the group comprising cellulose derivatives (low-substituted hydoxypropyl cellulose, carboxymethylcellulose, calciumcarboxymethylcellulose, cross-linked sodium carboxymethyl cellulose) and chemically modified starch/cellulose derivatives (carboxymethyl starch, sodiumcarboxymethyl starch, etc.).
Pharmaceutically acceptable demulsifying agents can be selected from, but not limited to, the group comprising colloidal clay (bentonite, etc.), metal hydroxides (magnesium hydroxide, aluminum hydroxide, etc.), anionic surfactant (sodium lauryl sulfate, calcium stearate, etc.), cationic surfactant or ionic surfactant (polyoxyethylene alkyl ether, fatty acid ester of polyoxyethylene sorbitan or sucrose esters of fatty acids).
Stabilizing agent and/or agents can be selected from agents such as antioxidants, chelating agents, alkalinizing agents and photoprotective agents. Antioxidants can be selected from, but not limited to, the group comprising substances such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium sulfite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylsistein, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate.
Chelating agents can be selected from, but not limited to, the group comprising disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
Alkalinizing agents can be selected from, but not limited to, alkali metal salts such as sodium carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines, Ν,Ν'- dibenzylemylenediamine, diemanolamine, ethylenediamine, meglumine, monosodium glutamate, polacryline sodium, sodium alginate.
Photoprotective agents can be selected from, but not limited to, a group comprising metal oxides such as titanium oxide, iron oxide or zinc oxide.
Pharmaceutically acceptable flavoring agents can be selected from, but not limited to, the group comprising sour cherry flavor, blackberry flavor, grapefruit flavor, grape flavor, pear flavor, orange flavor, apricot flavor or combinations thereof.
Pharmaceutically acceptable diluents can be selected from, but not limited to, the group comprising lactose, dry lactose, lactose monohydrate, directly compressed lactose (lactose D.C.), starch, hydrolyzed starch, mannitol, sorbitol, xylitol, dextrose, dextrose monohydrate, dibasic calcium phosphate dihydrate, monobasic calcium, sulfate monohydrate, calcium sulfate dihydrate, amylose, calcium carbonate, glycine, bentonite.
Pharmaceutically acceptable surfactants can be selected from, but not limited to, the group comprising sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, sugar esters of fatty acids and glycerides of fatty acids.
Pharmaceutically acceptable glidants can be selected from, but not limited to, the group comprising talc, silicone dioxide, magnesium trisilicate, cellulose powder, starch, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfates.
In addition to these, other pharmaceutically acceptable excipients such as solubility modulators, sweeteners, coloring agents and coating agents can also be used in the formulation.
Examples of pharmaceutically acceptable formulations of the present invention are given below. These examples are given to exemplify the present invention, but the invention is not limited to these examples.
EXAMPLES EXAMPLE 1:
The active agents telmisartan, amlodipine and indapamide are turn into a pharmaceutical composition by conventional methods in the prior art. The homogenous mixture obtained afterwards is dried and shaped as required.
EXAMPLE 2:
Preparation of the bilayer tablet composed of a fast release and a constant release layer comprises the following steps:
- Firstly, the constant release layer is prepared. In the constant release layer, there is only indapamide as the active agent. In the pharmaceutical composition, indapamide constitutes 5% of total amount of substances and pharmaceutically acceptable excipients with polymers providing constant release characteristic in addition. Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and sieved. They are mixed so as to provide homogeneity.
- There placed a layer which comprises telmisartan, amlodipine and indapamide surrounding the constant release layer. This layer is prepared according to
conventional tablet production methods with the addition of all the active agents and pharmaceutically acceptable excipients. The pharmaceutical composition comprises 5% indapamide; 10% amlodipine and 30% telmisartan of total substance amount. Afterwards, the homogenous mixture obtained is dried and shaped as required.
- Both mixtures prepared are pressed as bilayer tablet by imposing an appropriate compressive force. Firstly, the constant release layer is pressed, then the fast release layer is pressed around it.
- The tablet is coated with pharmaceutically acceptable coating materials.
EXAMPLE 3:
There is 2,5% indapamide in proportion to total substance amount of the pharmaceutical formulation in the constant release layer which is the innermost layer of the tablet. In order to provide constant release characteristic to this layer, polymers such as hydroxypropyl methyl cellulose, microcrystalline cellulose are added. Other excipients are also added into the pharmaceutical composition. Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and then sieved. They are mixed so as to provide homogeneity.
- The fast release layer surrounding the constant release layer comprises 5% indapamide, 10% amlodipine and 35% telmisartan in proportion to total substance amount of the pharmaceutical formulation. Said active agents are mixed with pharmaceutically acceptable excipients. Granulation solution is prepared according to methods in the prior art. The granules obtained are dried and then sieved. They are mixed so as to provide homogeneity.
- The composition is pressed into tablet form such that the constant release layer is the inner layer while the fast release layer is the outer layer.
- The tablet is coated with pharmaceutically acceptable coating materials.
Claims
1. A pharmaceutical composition characterized by comprising the active agents telmisartan, amlodipine and indapamide.
2. The pharmaceutical composition according to claim 1 characterized in that the active agents telmisartan, amlodipine and indapamide can be in free form or in the form of pharmaceutically acceptable salts, enantiomers, racemates, solvates, hydrates, different polymorphic forms or amorphous forms of the respective active agents.
3. The pharmaceutical composition according to claim 1 characterized in that the active agent amlodipine is in the form of besylate, mesylate or maleate salt.
4. The pharmaceutical composition according to claim 3 characterized in that the active agent amlodipine is in the form of besylate salt.
5. The pharmaceutical composition according to claim 1 characterized in that said composition comprises pharmaceutically acceptable excipients in addition to the active agents telmisartan, amlodipine and indapamide.
6. The pharmaceutical composition according to claim 1 characterized in that said composition is used in the production of a drug so as to be used in the treatment of diseases such as hypertension, acute and/or chronic heart failure, congestive heart failure, left heart failure, hypertrophic cardiomyopathy, arrhythmia, cardiomegalia, atrial fibrillation, embolism, ischemic heart disease, coronary artery disease, myocardial infarction, atherosclerosis, angina, renal failure, angina pectoris, diabetes, secondary aldosteronism, pulmonary hypertension, diabetic nephropathy, scleroderma, glomerulosclerosis, albuminuria, diabetic retinopathy, migraine, peripheral vascular diseases, Raynaud's phenomenon, cognitive disorders, hypertensive encephalopathy, thrombotic glaucoma and stroke.
7. The pharmaceutical composition according to claim 1 characterized in that said composition is used simultaneously, sequentially or separately.
8. The pharmaceutical composition according to claim 1 characterized in that the active agents in said composition are formulated separately so as to be used in a kit form.
9. The pharmaceutical composition according to claim 1 characterized in that said composition is formulated in the same dosage form.
10. The pharmaceutical composition according to claim 1 characterized in that said composition is administered by the oral route.
11. The phannaceutical composition according to claim 1 characterized in that said composition is formulated in solid dosage forms such as tablet; capsule; enteric coated or modified release tablets; prolonged release tablet; delayed release tablet; fast soluble tablet; effervescent tablet; effervescent granule; fast soluble powder mixture of dry powder mixture for syrup preparation; dragee; orally disintegrating tablet; water soluble tablet; water soluble powder, tablet or granule; film tablet; or liquid dosage forms such as suspension.
12. The pharmaceutical composition according to claim 1 characterized in that the amount of the active agents varies in the range of 0,5% to 95%, preferably in the range of 1% to 90% in proportion to total substance amount in the pharmaceutical composition.
13. The pharmaceutical composition according to claim 1 characterized in that the amount of telmisartan is in the range of 10-300 mg, the amount of amlodipine is in the range of 2,5-25 mg, the amount of indapamide is in the range of 0,1-10 mg in one dose of the phannaceutical composition.
14. The pharmaceutical composition according to claim 1 characterized in that said composition is formulated in compressed bilayer tablet form.
15. The pharmaceutical composition according to claim 14 characterized in that said tablet is composed of a constant release layer and a fast release layer.
16. The phannaceutical composition according to claim 15 characterized in that the constant release layer comprises the active agent indapamide.
17. The pharmaceutical composition according to claim 15 characterized in that the fast release layer comprises the active agents telmisartan, amlodipine and indapamide.
18. The pharmaceutical composition according to claim 15 characterized in that the active agent indapamide is used together with polymers providing constant release such as cellulose derivatives, particularly hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, methyl hydroxypropyl cellulose, carboxymethyl cellulose, povidone; acrylic acid copolymers or combinations thereof.
19. The pharmaceutical composition according to claim 15 characterized in that the constant release layer is formulated to be the innermost layer while the fast release layer surrounds the constant release layer.
20. The pharmaceutical composition according to claim 1 characterized in that the active agent combination comprises at least one binder, lubricant, disintegrant, demulsifying agent, stabilizing agent, flavoring agent, diluent, surfactant and glidant as the excipients.
21. The pharmaceutical composition according to claim 20, wherein the binder used in said composition is selected from a group comprising starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums (such as acacia); gelatin; cellulose derivatives (such as microcrystalline cellulose, HPC, HEC, HPMC, carboxymethyl cellulose, methyl cellulose, ethyl cellulose); povidone, polyvinylpyrrolidone polyethylene glycol; waxes; calcium carbonate; calcium phosphate; alcohols (such as sorbitol, xylitol, mannitol) and water.
22. The pharmaceutical composition according to claim 20, wherein the lubricant used in said composition is selected from a group comprising stearic acid, stearic acid salts (calcium state, magnesium stearate, etc.), talc, colloidal silica, wax, boric acid, adipic acid, sulfates (sodium sulfate), glycol, fumaric acid, sodium benzoate, DL-leucine, lauryl sulfate (sodium lauryl sulfate, magnesium lauryl sulfate.), silicates, starch derivatives.
23. The pharmaceutical composition according to claim 20, wherein the disintegrant used in said composition is selected from a group comprising cellulose derivatives (low- substituted hydoxypropyl cellulose, carboxymethylcellulose, calciumcarboxymethylcellulose, cross-linked sodium carboxymethyl cellulose) and chemically modified starch/cellulose derivatives (carboxymethyl starch, sodiumcarboxymethyl starch).
24. The pharmaceutical composition according to claim 20, wherein the demulsifying agent used in said composition is selected from a group comprising colloidal clay (bentonite), metal hydroxides (magnesium hydroxide, aluminum hydroxide), anionic surfactant (sodium lauryl sulfate, calcium stearate), cationic surfactant or ionic surfactant (polyoxyethylene alkyl ether, fatty acid ester of polyoxyethylene sorbitan or sucrose esters of fatty acids).
25. The pharmaceutical composition according to claim 20, wherein the stabilizing agent used in said composition is selected from a group comprising agents such as antioxidants, chelating agents, alkalinizing agents and photoprotective agents.
26. The pharmaceutical composition according to claim 25, wherein the antioxidant used in said composition is selected from a group comprising substances such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium sulfite, gallates (such as propyl gallate), tocopherol, citric acid, malic acid, ascorbic acid, acetylsistein, fumaric acid, lecithin, ascorbyl palmitate, ethylenediaminetetraacetate.
27. The pharmaceutical composition according to claim 25, wherein the chelating agent used in said composition is selected from a group comprising disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or combinations thereof.
28. The pharmaceutical composition according to claim 25, wherein the alkalinizing agent used in said composition is selected from a group comprising alkali metal salts such as sodium carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines, N,N'-dibenzylemylenediamine, diemanolamine, ethylenediamine, meglumine, monosodium glutamate, polacryline sodium, sodium alginate.
29. The pharmaceutical composition according to claim 25, wherein the photoprotective agents used in said composition are selected from a group comprising metal oxides such as titanium oxide, iron oxide or zinc oxide.
30. The pharmaceutical composition according to claim 20, wherein the flavoring agent used in said composition is selected from a group comprising sour cherry flavor, blackberry flavor, grapefruit flavor, grape flavor, pear flavor, orange flavor, apricot flavor or combinations thereof.
31. The pharmaceutical composition according to claim 20, wherein the diluent used in said composition is selected from a group comprising lactose, mannitol, glucose, sucrose, calcium sulfate, calcium phosphate, hydroxypropyl cellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, starch, polyvinylpyrrolidone, magnesium aluminamethasilicate or combinations thereof.
32. The pharmaceutical composition according to claim 20, wherein the surfactant used in said composition is selected from a group comprising sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters (polysorbates), polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene castor oil derivatives, docusate sodium, quaternary ammonium compounds, sugar esters of fatty acids and glycerides of fatty acids.
33. The pharmaceutical composition according to claim 20, wherein the glidant used in said composition is selected from a group comprising talc, silicone dioxide, magnesium trisilicate, cellulose powder, starch, tribasic calcium phosphate, metallic stearates, calcium silicate and metallic lauryl sulfates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11729785.3A EP2575808A1 (en) | 2010-05-28 | 2011-05-27 | Combination of antihypertensive agents |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201004315 | 2010-05-28 | ||
| TR2010/04315 | 2010-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011149438A1 true WO2011149438A1 (en) | 2011-12-01 |
Family
ID=44310842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2011/000153 WO2011149438A1 (en) | 2010-05-28 | 2011-05-27 | Combination of antihypertensive agents |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2575808A1 (en) |
| WO (1) | WO2011149438A1 (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107174570A (en) * | 2017-03-09 | 2017-09-19 | 苏州东瑞制药有限公司 | Stable Telmisartan Tablets of a kind of dissolving out capability and preparation method thereof |
| CN107375274A (en) * | 2017-07-25 | 2017-11-24 | 合肥华方医药科技有限公司 | The indapamide pharmaceutical composition that bioavilability improves |
| WO2018138578A1 (en) * | 2017-01-25 | 2018-08-02 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| WO2019098540A1 (en) * | 2017-11-15 | 2019-05-23 | Chong Kun Dang Pharmaceutical Corp. | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| WO2020021341A1 (en) * | 2018-07-26 | 2020-01-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US10723700B2 (en) | 2015-08-12 | 2020-07-28 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US10800779B2 (en) | 2015-04-03 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11247992B2 (en) | 2014-02-13 | 2022-02-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2023001880A1 (en) | 2021-07-22 | 2023-01-26 | Krka, D. D., Novo Mesto | Bilayer tablet comprising telmisartan and indapamide |
| EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
| RU2828226C2 (en) * | 2018-07-26 | 2024-10-08 | Зэ Джордж Инститьют Фор Глобал Хелс | Compositions for treating hypertension |
| EP4574148A1 (en) * | 2023-12-20 | 2025-06-25 | KRKA, d.d., Novo mesto | Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension |
| WO2025132571A1 (en) * | 2023-12-20 | 2025-06-26 | Krka, D.D., Novo Mesto | Immediate release monolayer tablet comprising telmisartan and one or more other antihypertensive agents, method of manufacturing the same, and its use |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3565911A (en) | 1968-03-06 | 1971-02-23 | Science Union & Cie | Disubstituted n-amino indoline compounds |
| EP0089167A2 (en) | 1982-03-11 | 1983-09-21 | Pfizer Limited | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them |
| EP0502314A1 (en) | 1991-02-06 | 1992-09-09 | Dr. Karl Thomae GmbH | Benzimidazol, medicaments containing them and process for their preparation |
| US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
| US20090275559A1 (en) * | 2008-04-30 | 2009-11-05 | Blue Note Pharmaceuticals, Inc. | Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina |
-
2011
- 2011-05-27 EP EP11729785.3A patent/EP2575808A1/en not_active Withdrawn
- 2011-05-27 WO PCT/TR2011/000153 patent/WO2011149438A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3565911A (en) | 1968-03-06 | 1971-02-23 | Science Union & Cie | Disubstituted n-amino indoline compounds |
| EP0089167A2 (en) | 1982-03-11 | 1983-09-21 | Pfizer Limited | Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them |
| EP0502314A1 (en) | 1991-02-06 | 1992-09-09 | Dr. Karl Thomae GmbH | Benzimidazol, medicaments containing them and process for their preparation |
| US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
| CN101450211A (en) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | Composite antihypertensive preparation |
| US20090275559A1 (en) * | 2008-04-30 | 2009-11-05 | Blue Note Pharmaceuticals, Inc. | Chronotherapeutic formulations of modified-release calcium channel blocker anti-hypertensive drugs in combination with other anti-hypertensive drugs for 24-hour optimal treatment of hypertension, nocturnal hypertension, and/or hypertension with angina |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Week 200951, Derwent World Patents Index; AN 2009-K61164, XP002659209 * |
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11247992B2 (en) | 2014-02-13 | 2022-02-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US11155532B2 (en) | 2014-02-13 | 2021-10-26 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US10968221B2 (en) | 2014-07-10 | 2021-04-06 | Incyte Corporation | Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US11401272B2 (en) | 2015-04-03 | 2022-08-02 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US10800779B2 (en) | 2015-04-03 | 2020-10-13 | Incyte Corporation | Heterocyclic compounds as LSD1 inhibitors |
| US10723700B2 (en) | 2015-08-12 | 2020-07-28 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US11498900B2 (en) | 2015-08-12 | 2022-11-15 | Incyte Corporation | Salts of an LSD1 inhibitor |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US20190314383A1 (en) * | 2016-11-15 | 2019-10-17 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| CN110545819A (en) * | 2017-01-25 | 2019-12-06 | 乔治全球健康研究院 | Composition for the treatment of hypertension |
| EP4374915A3 (en) * | 2017-01-25 | 2024-07-31 | The George Institute For Global Health | Compositions for the treatment of hypertension |
| JP2020506180A (en) * | 2017-01-25 | 2020-02-27 | ザ ジョージ インスティテュート フォー グローバル ヘルス | Composition for the treatment of hypertension |
| US12285415B2 (en) | 2017-01-25 | 2025-04-29 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US12102623B2 (en) | 2017-01-25 | 2024-10-01 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US10799487B2 (en) | 2017-01-25 | 2020-10-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| TWI852279B (en) * | 2017-01-25 | 2024-08-11 | 澳大利亞喬治全球健康研究所 | Compositions for the treatment of hypertension |
| US10322117B2 (en) | 2017-01-25 | 2019-06-18 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| TWI825279B (en) * | 2017-01-25 | 2023-12-11 | 澳大利亞喬治全球健康研究所 | Compositions for the treatment of hypertension |
| AU2018213147B2 (en) * | 2017-01-25 | 2023-08-31 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US20180243278A1 (en) * | 2017-01-25 | 2018-08-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| WO2018138578A1 (en) * | 2017-01-25 | 2018-08-02 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US11478462B2 (en) | 2017-01-25 | 2022-10-25 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| CN116327958A (en) * | 2017-01-25 | 2023-06-27 | 乔治全球健康研究院 | Composition for treating hypertension |
| JP2023063282A (en) * | 2017-01-25 | 2023-05-09 | ザ ジョージ インスティテュート フォー グローバル ヘルス | Compositions for treatment of hypertension |
| EP4101454A1 (en) * | 2017-01-25 | 2022-12-14 | The George Institute For Global Health | Compositions for use in the treatment of hypertension |
| CN107174570B (en) * | 2017-03-09 | 2019-11-05 | 苏州东瑞制药有限公司 | A kind of Telmisartan Tablets and preparation method thereof that dissolving out capability is stable |
| CN107174570A (en) * | 2017-03-09 | 2017-09-19 | 苏州东瑞制药有限公司 | Stable Telmisartan Tablets of a kind of dissolving out capability and preparation method thereof |
| CN107375274A (en) * | 2017-07-25 | 2017-11-24 | 合肥华方医药科技有限公司 | The indapamide pharmaceutical composition that bioavilability improves |
| WO2019098540A1 (en) * | 2017-11-15 | 2019-05-23 | Chong Kun Dang Pharmaceutical Corp. | Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt |
| WO2020021341A1 (en) * | 2018-07-26 | 2020-01-30 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| CN112770746A (en) * | 2018-07-26 | 2021-05-07 | 乔治全球健康研究院 | Composition for treating hypertension |
| RU2828226C2 (en) * | 2018-07-26 | 2024-10-08 | Зэ Джордж Инститьют Фор Глобал Хелс | Compositions for treating hypertension |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US11512064B2 (en) | 2018-08-31 | 2022-11-29 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| WO2023001880A1 (en) | 2021-07-22 | 2023-01-26 | Krka, D. D., Novo Mesto | Bilayer tablet comprising telmisartan and indapamide |
| EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
| EP4574148A1 (en) * | 2023-12-20 | 2025-06-25 | KRKA, d.d., Novo mesto | Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension |
| WO2025132532A1 (en) * | 2023-12-20 | 2025-06-26 | Krka, D.D., Novo Mesto | Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension |
| WO2025132571A1 (en) * | 2023-12-20 | 2025-06-26 | Krka, D.D., Novo Mesto | Immediate release monolayer tablet comprising telmisartan and one or more other antihypertensive agents, method of manufacturing the same, and its use |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2575808A1 (en) | 2013-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011149438A1 (en) | Combination of antihypertensive agents | |
| US8673945B2 (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
| JP2011500505A (en) | Solid formulation of olmesartan medoxomil and amlodipine | |
| AU2016366073A1 (en) | Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide | |
| CN101966181A (en) | Oral solid preparation containing candesartan and amlodipine and new application thereof | |
| JP2016512234A (en) | Pharmaceutical combination preparation | |
| CN102114017A (en) | Medicinal composition containing amlodipine and perindopril and application thereof | |
| MX2009000131A (en) | Immediate-release tablet formulations of a thrombin receptor antagonist. | |
| HK1221665A1 (en) | Composite formulation comprising tadalafil and amlodipine | |
| US20120141586A1 (en) | Thrombin receptor antagonist and clopidogrel fixed dose tablet | |
| JP5854371B2 (en) | Pharmaceutical preparation containing calcium antagonist / angiotensin II receptor antagonist | |
| US20080026050A1 (en) | Solid dose formulations of a thrombin receptor antagonist | |
| JP2015003915A (en) | Method for producing calcium channel blocker/angiotensin ii receptor antagonist-containing pharmaceutical formulation | |
| US6333361B1 (en) | Pharmaceutical composition containing zafirlukast | |
| CN102018708A (en) | Pharmaceutical composition containing amlodipine and atorvastatin magnesium | |
| TWI674907B (en) | A combination formulation comprising hmg-coa reductase inhibitor and calcium channel blocker | |
| US20120165386A1 (en) | Stable oral pharmaceutial composition of atorvastatin | |
| CN102000075A (en) | Novel pharmaceutical composite containing amlodipine and atorvastatin calcium anhydride | |
| RU2628538C2 (en) | Composition including amlodipine and losartan having improved stability | |
| CN109481437B (en) | Losartan potassium pharmaceutical preparation | |
| CN102805749A (en) | Dispersible tablet comprising clopidogrel and aspirin | |
| CN102266559A (en) | Pharmaceutical composition containing telmisartan salt and calcium ion antagonist | |
| CN102038682A (en) | Pharmaceutical composition containing amlodipine and atorvastatin calcium solvate | |
| WO2012050539A1 (en) | Pharmaceutical composition comprising eplerenone | |
| KR101148884B1 (en) | Composition for prevention or treatment hypertension comprising olmesartan medoxomil with an increased dissolution rate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11729785 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011729785 Country of ref document: EP |